Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind

Ibalizumab, an experimental antiretroviral agent that works differently than existing HIV drugs, demonstrated promising safety and antiviral activity in a small Phase 3 study of people with highly drug-resistant virus, according to a report at the IDWeek conference this week in New Orleans. If confirmed in larger studies, this could be good news for HIV patients who cannot be successfully treated using available therapies.

alt

Read more:

HIV Glasgow: 2-Drug HIV Therapy Just as Effective as Standard 3-Drug Therapy

Simplification of antiretroviral treatment to a boosted protease inhibitor and the nucleoside analog lamivudine -- a dual regimen -- is highly effective for people switching from a stable 3-drug regimen, researchers reported this week at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).

alt

Read more:

Resources for People with HIV and Hepatitis in Disaster Areas

During and after disasters such as Hurricane Matthew, people with medical conditions including HIV and viral hepatitis will be among those displaced and requiring emergency care. Government agencies offer resources for people with these and other chronic conditions, healthcare providers, and others who provide emergency and disaster-related services.

alt

Read more:

HIVR4P 2016: More Viral Suppression Needed to Reduce HIV Infections Among Gay Men

HIV suppression on antiretroviral therapy (ART) would need to increase substantially among men who have sex with men in order to take advantage of "treatment as prevention" to reduce the rate of new HIV infections, according to a mathematical modeling study presented at the HIV Research for Prevention conference (HIVR4P 2016) taking place this week in Chicago.

alt

Read more:

Media Reports of a British HIV Cure Breakthrough Are Premature

The Sunday Times yesterday reported that HIV had become undetectable in the blood of one man taking part in the RIVER study, a trial of an intensive treatment regimen designed to test whether it is possible to reduce levels of HIV-infected cells in the bodies of people recently infected with HIV. The Sunday Times reported that British scientists are on the "brink of an HIV cure." But in fact, the study is still in its early stages, participants are still on antiretroviral treatment, and it will not be able to describe participants as "cured" until extensive follow-up has taken place.

alt

Read more:

Researchers Observe Sustained Remission in Monkeys with HIV-Like Virus

Researchers have induced sustained remission of simian immune deficiency virus (SIV), a relative of HIV, in macaque monkeys treated with antiretroviral therapy (ART) and an antibody-based therapy used to treat inflammatory bowel disease, according to a report in the October 14 edition of Science. The monkeys not only had undetectable viral load for up to nearly 2 years after stopping treatment, but they also showed replenishment of key immune cells in the gut.

alt

Read more:

Sweden Becomes First Country to Achieve UNAIDS 90-90-90 Targets

Sweden has become the first country to achieve the UNAIDS/World Health Organization (WHO) 90-90-90 targets, research published in the August 18 advance edition of HIV Medicine shows. At the end of 2015, 90% of HIV cases in Sweden were diagnosed, 99.8% of people were linked to care, and 95% of people taking antiretroviral therapy for at least 6 months had a viral load below 50 copies/mL.

alt

Read more: